

+ DURA FIBER[◇] Ag PRO Dressings

The gelling action creates an optimal environment for healing wounds, reducing the risk of topical infection through sustained antimicrobial activity¹⁻⁶



Smith+Nephew

DURA FIBER[◇] Ag PRO

Wound Dressing
with Antimicrobial Silver
and Strengthening Cellulose Fibre

www.smith-nephew.com

Uses

Under the supervision of a healthcare professional, DURA FIBER Ag PRO Dressing may be used for the management of:

- Wounds with moderately to highly exuding wounds
- Superficial or deep wounds such as:
 - Partial thickness burns
 - Leg ulcers, pressure ulcers and diabetic ulcers
 - Surgical wounds (e.g., post-operative, wounds left to heal by secondary intent and donor/graft sites)
 - Traumatic wounds (e.g., abrasions and lacerations)

The number of individuals developing chronic wounds is increasing due to changing lifestyles and an ageing population. These wounds therefore present a major social and financial burden, not only for the affected individuals and their families, but also for healthcare systems around the world.⁷

Features and benefits

Highly absorbent
DURAFIBER® Ag PRO Dressing can absorb high volumes of exudate, absorbing 12 times its own weight.⁸

Contours to the wound bed
DURAFIBER Ag PRO Dressing contours to the surface of the wound bed, helping prevent voids for bacteria to collect, or for pooling exudate⁸

Minimised pain on removal
DURAFIBER Ag PRO Dressing forms a soft gel in contact with fluid, minimising pain and trauma to the wound bed upon removal.²⁻⁵

Broad spectrum antimicrobial
DURAFIBER Ag PRO Dressing starts to kill a broad range of pathogens including MRSA within 4 hours.^{*9,10}

One-piece removal
DURAFIBER Ag PRO Dressing has high tensile strength when wet, enabling ease in one-piece removal.^{1-5,11}

Through the gel formation, debris and any bacteria found in the wound exudate can be retained inside the fibre dressing and removed when the dressing is changed.^{1,12}



DURAFIBER Ag PRO Dressings

S+N Code	Size	Carton
66807677	5cm x 5cm	10
66807678	10cm x 10cm	10
66807679	15cm x 15cm	5
66807680	20cm x 30cm	5
66807681	2cm x 45cm	5
66807685	4cm x 30cm	5

*Based on in-vitro data

For detailed product information, including indications for use, contraindications, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area.



Smith+Nephew
Croxley Park, Building 5
Hatters Lane, Watford
Hertfordshire WD18 8YE
T +44 (0) 1923 477100
F +44 (0) 1923 477101

Smith+Nephew
Kay Fiskers Plads 9
2300 København S
Denmark
T: +45 45 80 61 00

Smith+Nephew
Krokslätt Fabrik 39
431 37 Mölndal
Sweden
T: +46 31 74 65 800

Smith+Nephew
Snarøyveien 36
1364 Fornebu
Norway
T: +47 66 84 20 20

Smith+Nephew
Lentäjantie 1
01530 Vantaa
Finland
T: +358 (0)207 866 333

◇Trademark of Smith+Nephew
All Trademarks acknowledged
©2024 Smith+Nephew
45479-ukinord 11/24

66807677 - FV000995, 66807678 - FV000971, 66807679 - FV000991, 66807680 - FV000997, 66807681 - FV000999, 66807685 - FV001002

References: 1. SFM (2022). Clinical Evaluation Report. Internal Report, SN0025. 2. SFM (2020). IOV (Traceability) Matrix. Internal Report, SN0003. 3. SFM (2020). Design Inputs. Internal Report, SN0013. 4. SFM (2022). Design Verification Report. Internal Report, SN0015. 5. SFM (2020). Design Validation Report. Internal Report, SN0017. 6. Smith+Nephew (2024). Internal Report, CSD.AWM.24.040. 7. Probst S, Apelqvist J, Bjarnsholt T, Lipsky BA, Ousey K, Peters EJG. Antimicrobials and Non-healing Wounds: An Update. *J Wound Management*, 2022;23(3Sup1):S1–S33. 8. Smith + Nephew (2024). Internal Report, CSD.AWM.24.035. 9. SFM (2020). Antimicrobial Stability Results Summary. Internal Report SN0030. 10. Smith+Nephew (2024). Internal Report, CSD.AWM.24.034. 11. SFM (2021). Usability Report. Internal Report, SN0001. 12. SFM (2023). Observational Study Report. Internal Report, SN0037.